Compare Globus Medical Inc. Class A Common Stock (GMED) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs MasTec Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while MasTec Inc trades at $191.47 (market cap $16.55B). The key difference: MasTec Inc is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and MasTec Inc for 25 Days on average.
| GMED | MTZ | |
|---|---|---|
Market Cap | $10.25B | $16.55B |
Volume | 1,108,124 | 1,530,865 |
Sector | Health | Industrials |
52-Week High | $96.82 | $437.51 |
52-Week Low | $58.33 | $190.08 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $9.76B | $19.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
MasTec (MTZ) trades at $206.12, down 0.35% on the day, with technical indicators showing bearish momentum below key moving averages. The company reported strong revenue growth from $14.3B in 2025 to $16.1B in 2026, with net income improving to $494M. Recent news highlights MTZ's record $21.4B backlog and positioning in AI infrastructure and power delivery markets, though cash flow volatility and premium valuation pose challenges.
Wall Street maintains strong bullish sentiment with 89% buy ratings and a $403.92 consensus price target, representing 96% upside potential. Key opportunities include infrastructure investment cycles and data center expansion, while risks include execution challenges, communications segment softness, and elevated P/E ratio of 32.8x.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
